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ABSTRACT Sepsis and septic shock remain serious consequences of infections, with
reported mortality rates in excess of 40 percent. Timely antibiotic therapy in cases of
sepsis and septic shock is recognized as an important determinant of outcome.
However, the administration of ineffective empirical treatment (IET) (an initial antibi-
otic regimen that is not active against the identiﬁed pathogen[s] based on in vitro
susceptibility testing results) is associated with excess mortality compared to effec-
tive empirical treatment (EET). We examined all hospitalized patients at Barnes-
Jewish Hospital with a sterile site (blood or pleural, abdominal, cerebrospinal, syno-
vial, and pericardial ﬂuid) culture positive for Gram-negative (GN) bacteria combined
with a primary or secondary ICD-9-CM code for severe sepsis (995.92) or septic
shock (785.52) between January 2010 and October 2015. Variables signiﬁcantly asso-
ciated with early-onset (48 h of hospitalization) IET of GN sterile site sepsis and
septic shock included age, recent hospitalization, and prior intravenous antibiotics.
Late-onset IET was associated with increasing numbers of hospitalization days before
infection onset and prior intravenous antibiotic administration. For patients with
early-onset infection, we found no difference in rates of survival between patients
receiving IET and EET. However, patients in the late-onset infection group receiving
IET had a statistically lower rate of survival than those receiving EET. These data sug-
gest that risk factors and outcomes for IET can vary based on the time of onset of
infection. Our results also highlight the importance of prior intravenous antibiotic
exposure as a risk factor for IET in infections by GN bacteria regardless of the time
of onset of infection.
KEYWORDS Gram-negative, sepsis
Sepsis and septic shock remain deadly clinical entities despite treatment withantimicrobials due in large part to the resistance of the underlying pathogens and
associated ineffective empirical treatment (IET) (1–4). The challenge to clinicians treat-
ing patients with sepsis is to determine which microorganisms should be covered with
the initial antibiotic regimen. Traditionally, this has been accomplished with knowledge
of the pathogens causing infections at the local hospital level, along with their
antimicrobial susceptibilities, and the assessment of speciﬁc patient types likely to
beneﬁt from empirical broad-spectrum antibiotics (5–7). Unfortunately, the use of
speciﬁc risk factors for analysis has been shown to result in limited overall accuracy in
determining the need for broad-spectrum antibiotic therapy and can result in unnec-
essary use of such agents (8). To further address this important issue, we performed a
cohort study to identify risk factors for IET of sepsis and septic shock caused by
Gram-negative (GN) bacteria on the basis of the time of onset of infection. The rationale
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for this study was to determine if the risk factors for IET among patients who were more
likely to have community-acquired infections differed from the risk factors for those
developing hospital-acquired infections.
RESULTS
We identiﬁed 855 consecutive patients with severe sepsis (n  246; 28.8%) or septic
shock (n  609; 71.2%) due to infection of a sterile site (blood or pleural, abdominal,
cerebrospinal, synovial, and pericardial ﬂuid) by GN bacteria. Early infection occurred in
520 patients (60.8%) and late infection in 225 patients (39.2%). The median (interquar-
tile range) time to infection in patients with late infection was 14 days (8 to 25). The
baseline characteristics obtained are shown in Tables 1 and 2.
IET occurred in 61 (11.7%) patients with early-onset infection and was associated
with a signiﬁcantly higher Charlson comorbidity index, more prior hospitalization, and
a higher incidence of intravenous antipseudomonal antibiotic therapy prior to admis-
sion (Table 1). Patients in the early-onset infection category that received IET were
signiﬁcantly more likely to be infected with Enterobacter sp. or Stenotrophomonas
TABLE 1 Baseline characteristics of study populationa
Characteristic
Value(s) for indicated time of onset




therapy (n  61)
Effective therapy




therapy (n  79)
Effective therapy
(n  256) P value
Age (yrs) (mean  SD) 0 64.7 15.1 61.9 14.1 0.154 0 59.0 14.5 57.5 14.9 0.409
Males 0 31 (50.8) 246 (53.6) 0.685 0 43 (54.4) 159 (62.1) 0.238
Race 6.7 6.6
African-American 0 20 (32.8) 143 (31.2) 0.771 0 18 (22.8) 47 (18.4) 0.417
Caucasian 0 34 (55.7) 282 (61.4) 0.405 0 56 (70.9) 180 (70.3) 1.000
Medical condition
Congestive heart failure 0 18 (29.5) 132 (28.8) 0.881 0 28 (35.4) 89 (34.8) 1.000
Chronic obstructive pulmonary
disease
0 16 (26.2) 143 (31.2) 0.464 0 25 (31.6) 78 (30.5) 0.889
Dementia 0 0 (0) 13 (2.8) 0.381 0 1 (1.3) 2 (0.8) 0.555
Cirrhosis 0 18 (29.5) 133 (29.0) 1.000 0 29 (36.7) 82 (32.0) 0.494
Chronic kidney disease 0 27 (44.3) 152 (33.1) 0.088 0 27 (34.2) 77 (30.1) 0.490
Diabetes mellitus 0 22 (36.1) 179 (39.0) 0.780 0 30 (38.0) 79 (30.9) 0.272
Underlying malignancy 0 21 (34.4) 165 (35.9) 0.887 0 42 (53.2) 140 (54.7) 0.897
Human immune deﬁciency virus
infection
0 0 (0) 7 (1.5) 1.000 0 2 (2.5) 2 (0.8) 0.237
Charlson comorbidity index, median
(IQR)
3.5 7 (4–9) 6 (4–8) 0.046 0.9 6 (4–8.75) 5 (4–8) 0.083
Priorb hospitalization 0 46 (75.4) 228 (49.7) 0.001 0 27 (34.2) 114 (44.5) 0.118
Receipt of antipseudomonal antibiotics
prior to hospitalization
3.5 26 (51.0) 109 (24.2) 0.001 0.9 22 (28.9) 56 (21.9) 0.219
Prior isolation of a Gram-negative
organism
0 2 (3.3) 11 (2.4) 0.657 0 26 (32.9) 49 (19.1) 0.013
Direct ICU admission 0 26 (44.8) 199 (43.4) 0.889 0 27 (34.2) 58 (22.7) 0.054
Direct oncology admission 0 7 (11.5) 54 (11.8) 1.000 0 23 (29.1) 104 (40.6) 0.084
Median (IQR) no. of hospital days prior
to infection
0 0 (0–0) 0 (0–0) 0.749 0 18 (8–30) 13 (8–24) 0.075
ICU prior to infection 0 6 (9.8) 21 (4.6) 0.114 0 48 (60.8) 113 (44.1) 0.010
Ventilator prior to infection 0 1 (1.6) 7 (1.5) 1.000 0 38 (48.1) 96 (37.5) 0.115
CVC prior to infection 0 6 (9.8) 37 (8.1) 0.621 0 71 (89.9) 234 (91.4) 0.656
Urinary catheter prior to infection 0 5 (8.2) 27 (5.9) 0.407 0 56 (70.9) 138 (53.9) 0.009
Prior antipseudomonal cephalosporin
during admission
0 0 9 (2.0) 0.608 0 45 (57.0) 120 (46.9) 0.124
Prior carbapenem during admission 0 2 (3.3) 6 (1.3) 0.239 0 43 (54.4) 60 (23.4) 0.001
Prior beta-lactam/beta-lactamase
inhibitor during admission
0 0 6 (1.3) 1.000 0 26 (32.9) 45 (17.6) 0.007
Prior ﬂuoroquinolone during admission 0 0 2 (0.4) 1.000 0 18 (22.8) 40 (15.6) 0.173
Prior aminoglycoside during admission 0 0 5 (1.1) 1.000 0 17 (21.5) 20 (7.8) 0.002
Prior nonantipseudomonal
cephalosporin during admission
0 0 4 (0.9) 0 21 (26.6) 58 (22.7) 0.544
Organ dysfunction during admission 0 0
Cardiovascular/shock 40 (65.6) 317 (69.1) 0.561 64 (81.0) 188 (73.4) 0.173
Respiratory 20 (32.8) 168 (36.6) 0.671 62 (78.5) 163 (63.7) 0.014
Hematologic 20 (32.8) 167 (36.4) 0.671 41 (51.9) 125 (48.8) 0.700
Renal 40 (65.6) 328 (71.5) 0.369 52 (65.8) 184 (71.9) 0.303
Hepatic 4 (6.6) 33 (7.2) 1.000 14 (17.7) 36 (14.1) 0.470
aData represent number (percent) of patients unless otherwise indicated. CVC, central vein catheter; ICU, intensive care unit; IQR, interquartile range.
bPrior, within the previous 90 days.
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maltophilia (Table 2). IET occurred in 79 (23.6%) patients with late-onset GN sterile site
infection. Patients receiving IET in the late-onset infection category were signiﬁcantly
more likely to have had a prior isolation of a GN organism. In addition, intensive care
unit (ICU) admission prior to GN sterile site infection; insertion of a urinary catheter prior
to infection; receipt of intravenous carbapenem, a beta-lactam/beta-lactamase inhibi-
tor, or aminoglycoside antibiotics; and respiratory failure occurred in signiﬁcantly more
IET patients in the late-onset infection category (Table 1). Patients with late-onset
infection receiving IET were signiﬁcantly less likely to have a bloodstream infection and
to be infected with Escherichia coli and/or Klebsiella sp. In contrast, these patients were
signiﬁcantly more likely to have a positive abdominal ﬂuid culture, and to be infected
by Acinetobacter sp., Burkholderia sp., and/or Stenotrophomonas maltophilia (Table 2).
Multivarite logistic regression analysis (MVLRA) revealed that the factors that were
independently associated with IET in patients with early-onset infection were different
from those independently associated with IET in patients with late-onset infection. In
patients with early-onset GN sterile site infection, the odds of receiving IET increased
2.5% with each increase in year of age and increased over 2-fold if the patient had
previously been hospitalized or had received intravenous antipseudomonal beta-
lactam antibiotics in the 90 days prior to admission. Factors independently associated
with IET in the late-onset infection group were days of hospitalization prior to infection
and receipt of intravenous carbapenem or beta-lactam/beta-lactamase inhibitor anti-
biotics in the 90 days prior to infection (Table 3). Both models demonstrated good ﬁt
based on the Hosmer-Lemeshow c-statistic P values (early, P  0.295; late, P  0.463).
Kaplan-Meier curves comparing rates of survival between patients receiving IET and EET
showed no difference in mortality in the early-onset infection group (Fig. 1A). Kaplan-
Meier curves for patients with late-onset infection demonstrated that patients receiving
IET had a statistically lower survival rate than patients receiving EET (Fig. 1B).
TABLE 2 Infection-related characteristicsa
Characteristic
Value(s) for indicated time of onset




therapy (n  61)
Effective therapy




therapy (n  79)
Effective therapy
(n  256) P
Culture site
Abdominal ﬂuid 0 8 (13.1) 43 (9.4) 0.359 0 21 (28.6) 24 (9.4) 0.001
Blood 0 53 (86.9) 419 (91.3) 0.245 0 56 (70.9) 231 (90.2) 0.001
Pleural ﬂuid 0 3 (4.9) 7 (1.5) 0.101 0 3 (3.8) 6 (2.3) 0.445
Other sterile site 0 0 2 (0.4) 1.000 0 0 1 (0.4) 1.000
Pathogens
Achromobacter sp. 0 2 (3.3) 2 (0.4) 0.070 0 2 (2.5) 1 (0.4) 0.140
Acinetobacter sp. 0 4 (6.6) 12 (2.6) 0.106 0 9 (11.4) 4 (1.6) 0.001
Burkholderia sp. 0 1 (1.6) 0 0.117 0 5 (6.3) 2 (0.8) 0.009
Citrobacter sp. 0 0 6 (1.3) 1.000 0 2 (2.5) 7 (2.7) 1.000
Enterobacter sp. 0 12 (19.7) 34 (7.4) 0.006 0 11 (13.9) 35 (13.7) 1.000
E. coli 0 20 (32.8) 200 (43.6) 0.129 0 8 (10.1) 75 (29.3) 0.001
Klebsiella sp. 0 11 (18.0) 111 (24.2) 0.337 0 10 (12.7) 72 (28.1) 0.004
Proteus sp. 0 2 (3.3) 34 (7.4) 0.294 0 1 (1.3) 6 (2.3) 1.000
Pseudomonas aeruginosa 0 12 (19.7) 71 (15.5) 0.456 0 13 (16.5) 65 (25.4) 0.127
Serratia sp. 0 0 10 (2.2) 0.615 0 2 (2.5) 14 (5.5) 0.377
Stenotrophomonas maltophilia 0 3 (4.9) 3 (0.7) 0.024 0 22 (27.8) 0 0.001
Antibiotic resistance
Cefepime 0 26 (42.6) 9 (2.0) 0.001 0 47 (59.5) 18 (7.0) 0.001
Meropenem 0 17 (27.9) 8 (1.7) 0.001 0 41 (51.9) 11 (4.3) 0.001
Piperacillin-tazobactam 5.7 26 (44.8) 68 (14.8) 0.001 0.8 41 (68.3) 69 (27.0) 0.001
Gentamicin 0 19 (31.1) 31 (6.8) 0.001 0 46 (58.2) 17 (6.6) 0.001
Ciproﬂoxacin 0 34 (55.7) 87 (19.0) 0.001 0 47 (59.5) 44 (17.2) 0.001
Ceftriaxone 0 54 (88.5) 132 (28.8) 0.001 0 72 (91.1) 124 (48.8) 0.001
Multidrug resistant 0 22 (36.1) 10 (2.2) 0.001 0 47 (59.5) 14 (5.5) 0.001
aIneffective therapy data and effective therapy data represent number (percent) of patients.
Ineffective-Treatment Risks in Gram-Negative Sepsis Antimicrobial Agents and Chemotherapy
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Our ﬁndings conﬁrm the importance of prior intravenous antibiotic exposure as a
risk factor for infection with antibiotic-resistant bacteria promoting IET (6, 9). We also
demonstrated that the risk factors and outcomes for IET differ according to the onset
of infection. The occurrence of a prior hospitalization for early-onset infections and days
of hospitalization prior to infection for late-onset infections both represent greater
exposure to the health care system. By increasing patient exposure to the health care
system, the likelihood of patient colonization and subsequent infection with antibiotic-
resistant bacteria is increased (6). Interestingly, hospital survival was impacted by IET
only in patients in the late-onset infection group. This may be related to these
infections occurring in individuals who are already hospitalized for other acute medical
and surgical conditions and are thus at greater risk for mortality from IET due to the
immune suppression resulting from their underlying disease process (10). Our results
also highlight the complexity of identifying septic patients who are at risk for receiving
IET due to the differences in risk factors for those with community-acquired infections
compared to those with hospital-acquired infections.
Empirical antibiotic treatment of severe GN infections, especially in hospitals, where
the presence of antibiotic-resistant infections is commonplace, can be problematic. On
the one hand, clinicians desire to provide effective initial treatment to patients with
serious infections in order to maximize clinical outcomes while trying to avoid the
unnecessary use of broad-spectrum antibiotics in order to minimize the further emer-
gence of resistance (11). Although we identiﬁed prior intravenous antibiotic exposure
as a risk factor for IET regardless of the time of infection onset, its identiﬁcation may be
problematic, particularly for patients who received antibiotic therapy at a different
hospital or in an outpatient setting. Most of the patients in our study had community-
acquired infections necessitating knowledge of the history of prior intravenous antibi-
otic administration at the time of hospital admission. Unfortunately, many patients and
their families may not know whether they received intravenous antibiotics in the
previous 90 days or may not have the capacity to remember such treatment. Medical
records from outside hospitals or outpatient treatment facilities are also frequently not
available when antibiotic decision-making occurs for patients newly admitted to the
hospital setting. For these reasons, surrogate markers for prior antibiotic exposure such
as prior hospitalization and residence in a nursing facility have been advocated for as
markers for high-risk infection with antibiotic-resistant bacteria and for the need for
broad-spectrum antibiotic therapy (12). However, the use of these risk factors to guide
the prescription of broad-spectrum antibiotics has been criticized for promoting un-
necessary use of these agents and potentially encouraging the emergence of further
antimicrobial resistance (13–15). Nevertheless, health care-associated infections are
common in the United States, with the Centers for Disease Control and Prevention
TABLE 3 Risk factors for ineffective therapy, as determined by multivariate logistic
regressiona
Factor




Hospital admission in the previous 90 days 2.257 (1.010–5.043)




No. of days to isolation of a GN pathogen 1.018 (1.001–1.037)
Receipt of intravenous carbapenem antibiotics prior to
isolation of a GN pathogen
5.726 (2.854–11.486)
Receipt of intravenous beta-lactam/beta-lactamase inhibitor
antibiotics prior to isolation of a GN pathogenb
2.171 (1.119–4.212)
aHosmer-Lemeshow c-statistic: early infection, P  0.295; late infection, P  0.463. GN, Gram-negative.
bIn the 90 days prior to the onset of infection.
Micek et al. Antimicrobial Agents and Chemotherapy
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estimating that more than 720,000 health care-associated infections occur in the United
States per year, with many of these being attributed to antibiotic-resistant pathogens
(16). This ﬁgure highlights the potential number of individuals for whom empirical
antibiotic prescription is problematic.
We and others have utilized various statistical methods in an attempt to develop
tools for guidance of administration of broad-spectrum antibiotics (5–7, 17–19). These
algorithms were developed with the primary goal of improving upon the identiﬁcation
of patients with serious infections, primarily pneumonia and bacteremia, attributed to
antibiotic-resistant bacteria. Given the limitations of methods for accurately identifying
patients with serious infections attributed to antibiotic-resistant bacteria, the use of
FIG 1 Kaplan-Meier curves for cumulative survival (Cum Survival), with the solid line representing
patients who received effective therapy and the hatched line representing patients who received
ineffective therapy. (A) Early culture group. (B) Late infection group.
Ineffective-Treatment Risks in Gram-Negative Sepsis Antimicrobial Agents and Chemotherapy
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rapid molecular diagnostics has been advocated as a means of more precisely selecting
empirical antibiotic treatment for such patients (20). Emerging data suggest that
patient outcomes, as well as enhancement of antimicrobial stewardship practices, can
be achieved with the use of these new technologies (21–23). Our study may provide
guidance for identifying which patients might beneﬁt the most from the application of
these diagnostics. Patients identiﬁed to be at risk for IET, due to the prior administration
of intravenous antibiotics, would be a reasonable group for the application of rapid
diagnostics in order to conﬁrm the need for broad-spectrum antibiotics and to
avoid their unnecessary use when the presence of resistant bacteria has not been
not identiﬁed (24).
Several limitations of our study should be recognized. First, the retrospective design
did not allow determination of the exact cause of mortality. Furthermore, it is possible
that we did not identify all cases of severe infections attributed to GN bacteria given the
constraints of our deﬁnition. Second, the data were derived from a single center, and
this necessarily limited the generalizability of our ﬁndings. As such, our results may not
reﬂect what one might see at other institutions. For example, Barnes-Jewish Hospital
has a regional referral pattern that includes community hospitals; regional long-term
acute care hospitals; nursing homes; and chronic wound, dialysis, and infusion clinics.
Patients transferred from these settings are more likely to be infected with potentially
antibiotic-resistant bacteria. Third, the selection of the 48-h threshold for early-onset
infection was based on our desire to compare individuals with community-acquired
infection to those having hospital-acquired infections and on the availability of patho-
gen identiﬁcation and antimicrobial susceptibility testing (AST) at our institution. It is
possible that our results would have differed had we selected a different threshold for
separating early-onset infection from late-onset infection.
Another limitation of our study was that we performed multiple statistical analyses
whereby some associations may have occurred by chance. Therefore, these ﬁndings
should be interpreted with caution. For example, we found that early-onset IET was
associated with prior intravenous administration of antipseudomonal beta-lactam an-
tibiotics whereas late-onset IET was associated with prior administration of intravenous
carbapenems and beta-lactam/beta-lactamase inhibitor antibiotics. These ﬁndings
were likely a function of the differences in the predominant classes of intravenous
antibiotics that patients received in the time period prior to their hospital admission
and during the course of their index hospital stay, respectively. The more important
results and conclusions from these data relate to the common link of prior intravenous
antibiotic exposure to the development of IET regardless of the timing of the infection.
In conclusion, we conﬁrmed the importance of prior intravenous antibiotic exposure
as a risk factor for the administration of IET. Clinicians prescribing antibiotics to patients
with serious infections likely caused by GN bacteria should attempt to identify the
presence of this risk factor, especially among patients with late-onset or hospital-
acquired infections. More importantly, there is an urgent need to identify better
methods to guide the use of empirical therapy in patients with potentially life-
threatening bacterial infections in this era of increasing antimicrobial resistance. Further
investigation of rapid microbiologic diagnostics techniques should include studies
aimed at improving the prescription of empirical antibiotic therapy in patients with
suspected GN bacterial sepsis and septic shock.
MATERIALS AND METHODS
Study population and data source. This study was conducted at Barnes-Jewish Hospital, an
academic referral center with 1,300 beds. The investigation was approved by the Institutional Review
Boards of Washington University and the St. Louis College of Pharmacy, and the need for informed
consent was waived. All patients hospitalized between January 2010 and October 2015 who showed the
presence of a sterile site (blood or pleural, abdominal, cerebrospinal, synovial, and pericardial ﬂuid)
culture positive for GN bacteria combined with primary or secondary ICD-9-CM codes for severe sepsis
(995.92) or septic shock (785.52) were eligible for inclusion. Data were collected from the hospital’s
electronic health record system provided by the Center for Clinical Excellence, BJC Healthcare.
Micek et al. Antimicrobial Agents and Chemotherapy
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Study outcomes. The primary objective of this study was to identify the occurrence of early-onset
and late-onset IET. The secondary objective of this study was to identify variables predicting IET among
patients with early-onset and late-onset GN bacterial infection.
Deﬁnitions and study design. All deﬁnitions were prospectively selected prior to study initiation.
Patients were categorized as early-onset infection if the GN pathogen was isolated within 48 h of hospital
admission and late-onset infection if the GN pathogen was isolated after 48 h. IET was deﬁned as an
initial antibiotic regimen that was not active against the identiﬁed pathogen(s) based on in vitro
susceptibility testing. Patients that were infected with an extended-spectrum--lactamase (ESBL)-
producing organism(s) had to have received a carbapenem to be categorized as EET patients. Similarly,
patients infected with organisms likely to produce AmpC -lactamase (Enterobacter species, Serratia
species, Citrobacter freundii) who initially received piperacillin-tazobactam were categorized as IET
patients given that exposure to this antibiotic can lead to high-level expression of this enzyme, which can
in turn lead to resistance or enhanced selection of resistant mutants during therapy. Only the ﬁrst
episode of sterile site infection was evaluated, but, in cases in which a GN pathogen(s) was isolated
simultaneously from multiple sites (i.e., abdominal ﬂuid and blood), all of the sites were accounted for
in the results. Patients were excluded if an organism other than a GN species was isolated. For
polymicrobial GN infections, the initial antimicrobial regimen had to be active against all pathogens to
be classiﬁed as EET.
Prior intravenous antibiotic exposure was assessed using the BJC Healthcare Informatics database.
Barnes-Jewish Hospital is the main teaching institution for BJC Healthcare, a large integrated health care
system of both inpatient and outpatient care facilities. The system includes 13 hospitals in a compact
geographic region surrounding and including St. Louis, MO. Barnes-Jewish Hospital has 50,000
admissions annually and the BJC system 140,000.
Antimicrobial monitoring. From January 2002 through the present, Barnes-Jewish Hospital utilized
an antibiotic control program to help guide antimicrobial therapy for bacterial infections. During that
time period, the use of cefepime, gentamicin, or vancomycin was unrestricted. However, initiation
of intravenous ciproﬂoxacin, imipenem, meropenem, piperacillin-tazobactam, linezolid, ceftolazone-
tazobactam, ceftazidime-avibactam, or daptomycin administration was restricted and required preau-
thorization from either a clinical pharmacist or an infectious diseases physician. Each intensive care unit
(ICU) and the emergency department had a clinical pharmacist who reviewed all antibiotic orders to
ensure that the dosing and interval of antibiotic administration were adequate for individual patients
based on body size, renal function, and the resuscitation status of the patient. After daytime hours, the
on-call clinical pharmacist or infectious diseases physician reviewed and approved the antibiotic orders.
The initial antibiotic dosages employed for the treatment of bacterial infections at the Barnes-Jewish
Hospital were as follows: cefepime, 1 to 2 g every 8 h; piperacillin-tazobactam, 4.5 g every 6 h; imipenem,
0.5 g every 6 h; meropenem, 1 to 2 g every 8 h; ciproﬂoxacin, 400 mg every 8 h; gentamicin, 5 mg/kg
of body weight once daily; vancomycin, 15 mg/kg every 12 h; linezolid, 600 mg every 12 h; ceftolazone-
tazobactam, 1.5 g every 8 h; ceftazidime-avibactam, 2.5 g every 8 h; daptomycin, 6 mg/kg every 24 h
(daptomycin was not prescribed for pneumonia).
Empirical therapy for patients with identiﬁed risk factors for infection with antibiotic-resistant GN
bacteria in the ICUs and emergency department of Barnes-Jewish Hospital usually consists administration
of an antipseudomonal penicillin (pipercillin-tazobactam) or a fourth-generation cephalosporin (cefepime) or
a carbapenem (meropenem). An aminoglycoside is often also administered as a single dose in patients
with septic shock and can be continued beyond the ﬁrst 24 to 48 h depending on the patient’s clinical
response and availability of antimicrobial susceptibility data (25, 26).
Antimicrobial susceptibility testing and local antibiogram. The microbiology laboratory of
Barnes-Jewish Hospital uses a VersaTREK automated microbial detection system (ThermoFisher Scientiﬁc,
Waltham, MA) for blood and sterile site cultures and a Bruker BioTyper matrix-assisted laser desorption
ionization–time of ﬂight mass spectrometry (MALDI-TOF MS) system (Bruker, Billerica, MA) for pathogen
identiﬁcation. Antimicrobial susceptibility testing (AST) of the bacterial isolates was performed using the
disk diffusion method according to guidelines and breakpoints established by the Clinical Laboratory and
Standards Institute and published during the inclusive years of the study (27). All classiﬁcations of
antibiotic resistance were based on in vitro susceptibility testing using these established breakpoints.
Although the time to AST is highly variable, AST is available for most cases of infections by GN bacteria
within 48 h of the culture signaling positive.
We recently published our data on the susceptibility patterns for GN bacterial infection causing sepsis
and septic shock in bacteremic patients (19). Resistance to pipercillin-tazobactam was found in 462
(28.6%) of the isolates, while 352 (21.8%) were resistant to cefepime and 138 (8.5%) were resistant to
carbapenems. A total of 153 isolates were resistant to both pipercillin-tazobactam and cefepime, and 106
(6.6%) were resistant to all 3 drugs of interest. The rate of extended-spectrum--lactamase identiﬁcation
was 3.3% (54 of 1,618 isolates), and the rate of carbapenase producers was 0.5% (8 of 1,618 isolates).
Data collection and statistical analysis. We collected data on demographic characteristics (age,
race, and sex), comorbidities of interest (hemodialysis, immunosuppression, Charlson score, previous
hospitalizations, and prior antibiotic therapy), clinical features (need for vasopressors or mechanical
ventilation, central vein catheter, duration of hospitalization before bacteremia), microbiology (culture
results and antibiotic susceptibility), treatment variables, and outcomes (hospital mortality).
Continuous variables were reported as means with standard deviations or medians with 25th and
75th percentiles according to the distribution. The Student t test was used for comparing normally
distributed data, and the Mann-Whitney U test was employed to analyze non-normally distributed data.
Categorical data were expressed as frequency distributions, and the chi-square or Fisher’s exact test was
Ineffective-Treatment Risks in Gram-Negative Sepsis Antimicrobial Agents and Chemotherapy





ber 23, 2017 by W







used to determine if differences existed between groups. The relationship between IET and hospital
mortality was evaluated by the use of the Kaplan-Meier method and the log rank test. We performed
univariate analysis and MVLRA to identify risk factors associated with IET. All risk factors that were
signiﬁcant at 0.20 in the univariate analyses were included in the corresponding multivariable analyses.
All variables entered into the models were examined for colinearity using the variance inﬂation factor
(VIF) as a colinearity statistic. The model’s goodness of ﬁt was assessed via determination of the
Hosmer-Lemeshow c-statistic. All tests were two-tailed, and a P value of 0.05 represented statistical
signiﬁcance (IBM SPSS Statistics, version 22.0 [SPSS]).
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